Target intelligence / Profile preview

B-cell receptors and antibodies specific for H1 hemagglutinin and N1 neuraminidase (H1N1-specific BCRs/Abs)

Target
H1N1-specific BCRs/Abs
Molecular classification
Receptor, Immunoglobulin, Glycoprotein
01

Overview

B-cell receptors (BCRs) and antibodies specific for H1 hemagglutinin (HA) and N1 neuraminidase (NA) are the primary mediators of adaptive immunity against H1N1 influenza A viruses. Hemagglutinin is a surface glycoprotein that facilitates viral entry by binding to host cell sialic acid receptors, while neuraminidase is an enzyme required for the release of new viral particles from the cell surface (Nature, 2009, 459:1122-1125). Antibodies targeting the H1 head domain provide potent, strain-specific neutralization, whereas those targeting the conserved H1 stem or the N1 active site often provide broader protection across different H1N1 variants (Science, 2011, 333:850-856). These immunological components are the central targets of seasonal and pandemic influenza vaccines, which aim to elicit protective titers to prevent infection and reduce disease severity (The Lancet, 2012, 379:1413-1424). In addition to active immunization, monoclonal antibodies (mAbs) directed against these antigens are being developed as passive immunotherapies for severe influenza, offering a potential alternative when small-molecule antivirals like oseltamivir face resistance (Journal of Clinical Investigation, 2015, 125:125-131). Monitoring the specificity and durability of these B-cell responses is essential for the design of next-generation universal influenza vaccines.

Other names
Anti-H1N1 antibodiesH1-specific B-cell receptorsN1-specific B-cell receptorsInfluenza A H1N1 antibodiesAnti-hemagglutinin H1 antibodiesAnti-neuraminidase N1 antibodiesH1N1-neutralizing antibodies
02

Mechanism of action

Antibodies bind to the globular head or stem region of H1 hemagglutinin to block viral attachment to sialic acid receptors and prevent membrane fusion, or bind to the active site of N1 neuraminidase to inhibit the enzymatic cleavage of sialic acid, thereby preventing the release of progeny virions from infected host cells (Nature, 2009, 459:1122-1125; Science, 2011, 333:850-856).

03

Biological functions

Immune responseAntigen recognitionViral neutralizationOpsonizationAntibody-dependent cellular cytotoxicity (ADCC)Complement activation
04

Disease associations

InfectionInfluenza A virus infection
05

Safety considerations

Antigenic drift leading to immune evasionOriginal antigenic sin (impaired response to new strains due to prior exposure)Antibody-dependent enhancement (ADE)Hypersensitivity or allergic reactions to vaccine componentsAutoimmune cross-reactivity (e.g., Guillain-Barre syndrome, though rare)
06

Interacting drugs

Inactivated influenza vaccine (e.g., Fluzone, Fluarix)

6 more in the full profile.

07

Biomarkers

Hemagglutination inhibition (HAI) titerNeuraminidase inhibition (NAI) titerMicroneutralization assay (MN) titerMemory B-cell frequency (ELISpot)Serum IgG/IgA levels

Beyond the preview

Go deeper on B-cell receptors and antibodies specific for H1 hemagglutinin and N1 neuraminidase (H1N1-specific BCRs/Abs).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on B-cell receptors and antibodies specific for H1 hemagglutinin and N1 neuraminidase (H1N1-specific BCRs/Abs).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call